Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rinalt is a Class IIa medical device nasal spray developed by Aurora Biofarma for the management of respiratory conditions characterized by nasal mucus hypersecretion and congestion. The product is formulated with the proprietary Mucotannil Complex, seawater, purified water, dexpanthenol, and essential oils. Rinalt functions by creating a protective barrier on the nasal mucosa, facilitating the rapid and effective removal of excess mucus, and hydrating dry or irritated membranes. It is indicated for the treatment of the common cold, rhinitis, acute or chronic rhinosinusitis, and both wet and dry forms of allergic rhinitis. The device is approved for use in adults and children over 6 years of age and is CE certified (CE 0426).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rinalt.